Ranbaxy reports Q2
GURGAON, India — Consolidated sales for generic drug maker Ranbaxy Labs totaled $588 million in the second quarter ended June 30, a 28% rise over the year-ago period, the company said.
The drug maker reported that North American sales soared 140% over the year-ago period to a total of $272 million, aided by strong base business. U.S. sales for Ranbaxy were $255 million for the quarter, thanks to strong base business and exclusivity sales of such drugs as atorvastatin and atorvastatin and amlodipine (Lipitor and Caduet, respectively).
Ranbaxy added that during the quarter, it fortified its dermatology portfolio with two approvals from the Food and Drug Administration: Absorica — a novel, patented brand formulation of the acne medication isotretinoin, developed by Cipher, for the treatment of severe recalcitrant nodular acne, which the company expects to launch by the end of 2012 — and Ximino, a novel, patented brand formulation for the treatment of moderate to severe non-nodular acne.
"Sales and profitability grew in the Quarter with overall improvement across major regions, aided further by exclusivity sales in some of the key markets," Ranbaxy managing director and CEO Arun Sawhney said. "We capitalized on our product focus approach with the successful monetization of the atorvastatin and atorvastatin + amlodipine opportunities. The strategy to build long-term, differentiated value drivers was rewarded with two NDA approvals in the dermatological space in the USA."
Target Clinics offering cosmetic services
MINNEAPOLIS — Target’s in-store health clinics recently started offering consultations for eyelash lengthening and the treatment of hyperpigmentation of the skin and unwanted facial hair, according to a local news report.
The Pioneer Press reported that Target Clinics this summer began offering consultations for Latisse for eyelash lengthening; Vaniqa, which is for unwanted facial hair; and a treatment for hyperpigmentation of the skin. Target Clinic won’t actually dispense the medications but is charging $49 for a consultation that will result in a prescription for the medication, the article stated. The cosmetic prescriptions consultations are for those 18 years of age and older.
As previously reported by Drug Store News, RediClinic — which has 29 clinic locations at select H-E-B stores in Houston, Austin and San Antonio — also offers cosmetic services.
For $59 each, RediClinic patients can receive a consultation on Latisse; Lustra, which is a prescription cream that lightens freckles, age spots and other discolorations of the skin; and Vaniqa for unwanted facial hair.
Upsher-Smith buys British drug maker
MAPLE GROVE, Minn. — Upsher-Smith Labs has finalized its purchase of a British company that makes drugs for central nervous system and inflammatory disorders, the former said Tuesday.
Upsher-Smith announced that it completed its acquisition of Proximagen in a deal originally announced in June. Upsher-Smith said the $555 million deal would support the acceleration of its strategy to develop central nervous system drugs. Its currently pipeline includes USL255 (topiramate), an extended-release treatment for epilepsy in phase-3 development, and USL261 (midazolam), an intranasal treatment for seizures also in phase-3 development that has received the Food and Drug Administration’s orphan drug designation.
"The acquisition of Proximagen adds significantly to our scientific capabilities and supports the acceleration of our vision of becoming a leader in the CNS category," Upsher-Smith president and CEO Mark Evenstad said. "The combination of Upsher-Smith’s clinical development and commercialization expertise with Proximagen’s research and development platform provides the opportunity to further enhance our ability to bring new therapies to market to benefit patients."